Boehringer Ingelheim and Lilly Cardiology

 

Boehringer Ingelheim and Lilly Cardiology
N

Optimal Medical Therapy for Patients with HFrEF - Four Pharmacological Pillars

By Boehringer Ingelheim and Lilly Cardiology FEATURING Narendra Singh, Norman Lepor, Karol Watson, Matthew Budoff, Robert Chilton
By Boehringer Ingelheim and Lilly Cardiology FEATURING Narendra Singh, Norman Lepor, Karol Watson, Matthew Budoff, Robert Chilton
315 views
October 9, 2024

Copyright © 2024 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. 
(09/24) PC-US-140161

Comments are disabled for this content.

Featured Video

01:50
Boehringer Ingelheim and Lilly Cardiology

Embracing the Importance of HFrEF and HFpEF GDMT

Feat. M. Budoff

Featured Video

02:02
Boehringer Ingelheim and Lilly Cardiology

Overcoming Barriers to HFrEF GDMT Use

Feat. N. Singh
Heart Failure
01:50
Boehringer Ingelheim and Lilly Cardiology

Embracing the Importance of HFrEF and HFpEF GDMT

Feat. M. Budoff
02:02
Boehringer Ingelheim and Lilly Cardiology

Overcoming Barriers to HFrEF GDMT Use

Feat. N. Singh
03:03
Boehringer Ingelheim and Lilly Cardiology

The Shift to Rapid Sequencing to Improve Patient Outcomes in HFrEF

Feat. K. Watson
11
Boehringer Ingelheim

Timely Implementation of HFrEF GDMT

Feat. N. Singh
01:35
Boehringer Ingelheim and Lilly Cardiology

Championing the Pump Up GDMT Movement

Feat. N. Lepor
03:26
Boehringer Ingelheim and Lilly Cardiology

Optimal Medical Therapy for Patients with HFrEF - Four Pharmacologic…

Feat. N. Singh, N. Lepor, K. Watson, M. Budoff, R. Chilton